Hofmann B, Greiner J, Glusa E, Kertscher H P, Ostermann G
Institute für Pathologische Biochemie, Medizinische Akademie, Erfurt, BRD.
Haemostasis. 1991;21(2):77-84. doi: 10.1159/000216207.
The ether phospholipid KO-286011, which is related to platelet-activating factor (PAF), was examined for PAF-antagonistic action on rabbit platelets both in vitro and ex vivo. It inhibited the aggregation of washed platelets induced by PAF (5 nmol/l) concentration dependently (IC50 = 6.5 X 10(-7) mol/l). After injecting 0.5 mg/kg to rabbits, the ex vivo PAF-mediated aggregation in heparinized platelet-rich plasma was influenced selectively. The inhibition was short and maximal after 5 min. In contrast, hematocrit, counts of peripheral platelets and leukocytes, hemoglobin content, partial thromboplastin time, prothrombin time, and fibrinolytic activity in plasma were not affected. However, the therapeutic range of KO-286011 is limited because of membranolytic activity at higher dosages, leading to hemolysis and drop of circulating platelet counts.
与血小板活化因子(PAF)相关的醚磷脂KO - 286011在体外和体内对兔血小板的PAF拮抗作用进行了研究。它浓度依赖性地抑制PAF(5 nmol/l)诱导的洗涤血小板聚集(IC50 = 6.5×10(-7)mol/l)。给兔注射0.5 mg/kg后,富含血小板的肝素化血浆中体内PAF介导的聚集受到选择性影响。抑制作用短暂,5分钟后达到最大。相比之下,血细胞比容、外周血小板和白细胞计数、血红蛋白含量、部分凝血活酶时间、凝血酶原时间以及血浆中的纤溶活性均未受到影响。然而,由于较高剂量时的膜溶解活性,KO - 286011的治疗范围有限,会导致溶血和循环血小板计数下降。